Candesartan
Follicular carcinoma is more aggressive than papillary carcinoma. Ten year survival is 50%. Plasma thyroglobulin levels can be monitored for recurrence.
Peritoneal-membrane transport data As detailed in Table 1, among the 4 experimental periods, there were no significant differences in the following parameters: net ultrafiltration, D P urea, MTAC urate, 2-microglobulin clearance, and glucose absorption rate. Following 6-week candesartan treatment, there were significant decreases in the values of peritoneal albumin clearance p 0.05 ; and 4-hour albumin loss p 0.05 ; Fig. 2, 3 ; . The reduced values of both parameters remained to be observed following 12-week candesartan therapy p 0.05 ; . After 12-week candesartan withdrawal, the values of both parameters returned to the baseline levels Fig. 2, 3 ; . Despite the reduction in the peritoneal loss of albumin during candesartan treatment, serum albumin levels were not significantly different among the 4 periods Table 1 ; . Adverse effects During treatment with candesartan, no adverse effects including hyperkalemia or increasing the dosage of erythropoietin had been found Table 1 ; . Discussion The results in the present study have demonstrated that in hypertensive CAPD patients 1 ; candesartan at the dose of 8-16 mg day could effectively control blood pressure below 140 90 mmHg, 2 ; candesartan could reduce peritoneal albumin clearance and 4-hour albumin loss, 3 ; candesartan did not alter other peritoneal membrane transports, and 4 ; candesartan did not cause serious adverse effects including hyperkalemia and increased erythropoietin dosage.
NON-PREFERRED tier 3 ; Drugs generic chemical ; name. common brand trade ; name amlodipine-benazepril. LOTREL L ; candesartan-HCTZ. ATACAND HCT L ; enalapril-felodipine. LEXXEL L ; eprosartan-HCTZ. TEVETEN HCT L ; losartan-HCTZ. HYZAAR L ; nadolol-bendroflumethiazide. CORZIDE L ; quinapril-HCTZ. ACCURETIC L ; telmisartan-HCTZ. MICARDIS HCT L ; trandolapril-verapamil. TARKA L ; valsartan-HCTZ. DIOVAN-HCTZ L.
Calusterone Camazepam Camphor Cajdesartan Captodiame Captopril Carazolol Carbachol Carbamezapine Carbidopa + levodopa Carbinoxamine Carbromol Carfentanil Carisoprodol Carphenazine Carpipramine Carprofen Carteolol Carticaine see articaine ; Rela, Soma Proketazine Prazinil Rimadyl Cartrol Septocaine; Ultracaine, etc. Coreg Atcand Covatine Capolen Carbacel, Conducton Lentin, Doryl Tegretol Sinemet Clistin Mifudorm.
Candesartan tablets weight gain
Another trial, the Valsartan in Acute Myocardial Infarction VALIANT ; , compared the efficacy and safety of long-term treatment with valsartan with captopril, and their combination in highrisk patients after acute MI. This trial enrolled 14, 703 patients who either developed acute LVF based on clinical and or radiological signs ; or were diagnosed to have reduced LV function EF 35% ; within 12h to 10 days of an acute MI from 950 centers in 24 countries. Patients were randomised to the three arms of the study; Captopril only 150mg day ; , valsartan only 320mg day ; or Captopril 150mg + valsartan 160mg day. The study concluded that in patients with MI complicated by heart failure or left ventricular dysfunction or both, Valsartan is as effective as a proven dose of captopril in reducing the risk of all cause mortality as well as CV mortality, nonfatal MI and heart failure admissions. The combination of valsartan with a proven dose of captopril produced no further reduction in mortality but showed increased adverse drug effects, especially renal impairment and hyperkalemia. Interestingly, in view of the prior ValHeFT data suggesting a potential safety issue with the concomitant use of valsartan in patients already on beta-blocker and an ACEI, analysis of the data from the subgroup of patients already on beta blockers in the VALIANT trial with a 70% baseline beta-blocker use the VALIANT study had over 10, 000 patients on a beta-blocker randomized to either captopril, valsartan or both i.e. so called triple therapy ; did not show any adverse effects on composite CV outcome or death when valsartan was given concomitantly with a beta-blocker, either alone or with an ACE inhibitor. A plausible explanation offered by the authors is that unlike the Val-HeFT study, the combination arm of the VALIANT used only half the doses of valsartan which may therefore have prevented the adverse effects of triple therapy reported by the earlier Val-HeFT study. The "Candesartan in Heart Failure - Assessment of Reduction in mortality and Morbidity CHARM ; study, published in late 2003, reported that the angiotensin II receptor blocker ARB ; candesartan significantly reduces the risk of cardiovascular CV ; deaths and hospital admissions for heart failure HF ; , compared with placebo in patients with chronic HF. Overall, the CHARM study recruited 7601 patients mean age 66 years, New York Heart Association class II-IV ; at 618 centers in 26 countries and included 3 sub-studies; CHARM-Alternative trial n 2028 ; examined the effects of candesartan in patients with a reduced left ventricular ejection fraction LVEF ; who were ACE inhibitor intolerant; CHARM-Added n 2548 ; included patients with a depressed LVEF, but those who were already being treated with ACE inhibitors i.e. candesartan was prescribed on top of ACEI and CHARM-Preserved n 3025 ; investigated the effect of candesartan in those with a preserved LVEF most of whom were not treated with ACE inhibitors. Patients received candesartan titrated to 32 mg once daily or matching placebo, and were followed up for at least 2 years for a primary endpoint of combined CV death or CHF hospitalization. The primary outcome for the overall program was all-cause mortality. Overall, when results from the three component trials were combined, there was a trend towards lower "all-cause mortality" of 9% with active treatment, with this endpoint occurring in 23% of candesartan-treated patients, and 25% of those given placebo p 0.055 ; . There was, however, a significant 12% ; reduction in overall "CV mortality" with candesartan over placebo 18% vs 20%, p 0.012 ; , and also 21% fewer hospital admissions for CHF 20% vs 24%, p 0.0001 ; . Therefore, to prevent one CV death or hospitalization for HF, 23 patients would need to be treated for the trial period, of approximately three years. Looking individually at the sub-studies, CHARM-Alternative results showed that, after 33.7 months of treatment, patients given candesartan were 23% less likely to experience CV death or CHF hospitalization compared with those who received placebo 40.0% vs 33.0%, p 0.0004 ; and the treatment effects began early after 3-6 months ; . There were significant reductions in the number of patients hospitalized for CHF as well as in the total number of hospitalization for CHF.
9. Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry V, Baltimore: Williams & Wilkins, 1989. 10. Deb S, Thomas M, Bright C. Mental disorder in adults with intellectual disability. I: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years. Journal of Intellectual Disability Research 2001; 45 6 ; : 495-505. 11. Gillberg C, Presson E, Grufman M, Themner U. Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. British Journal of Psychiatry 1986; 149: 68-74. Mental Retardation and Developmental Disabilities: including a section on Down Sydrome, in ; City Health Information: New York City Department of Health and Mental Hygiene 2003; 22 4 ; : 1-7. 13. Moldavsky M, Lev D, Lerman-Sagie T. Behavioral phenotypes of genetic syndromes: a reference guide for psychiatrists. J. Am. Acad. Child. Adolesc. Psych 2001; 40 7 ; : 749-761. 14. Kastner T, Walsh KK, Fraser M. Undiagnosed medical conditions and medication side effects presenting as behavioral psychiatric problems in people with mental retardation. Mental Health Aspects of Developmental Disabilities, July August September 2001; 4 3 ; : 101-107 and ciloxan.
Candesartan more drug side effects
Anti-atherosclerotic and renoprotective effects of rosuvastatin and candesartan dr.
DESOGESTREL & ETHINYL ESTRADIOL TAB 0.15 MG-30 MCG TRIAMCINOLONE ACETONIDE OINT 0.05% PHENYLPROPANOLAMINE-GG TAB SR 12HR 75-1200 MG LEFLUNOMIDE TAB 100 MG LEFLUNOMIDE TAB 10 MG LEFLUNOMIDE TAB 20 MG DONEPEZIL HYDROCHLORIDE TAB 10 MG DONEPEZIL HYDROCHLORIDE TAB 5 MG ANASTROZOLE TAB 1 MG TRIAMCINOLONE TAB 4 MG DOSE PACK TRIAMCINOLONE ACETONIDE OINT 0.5% TRIAMCINOLONE TAB 4 MG TRIAMCINOLONE ACETONIDE CREAM 0.5% THYROID TAB 15 MG THYROID TAB 240 MG THYROID TAB 300 MG EXEMESTANE TAB 25 MG DICLOFENAC W MISOPROSTOL TAB 50-0.2 MG DICLOFENAC W MISOPROSTOL TAB 75-0.2 MG ASPIRIN W CODEINE TAB 325-30 MG ASPIRIN W CODEINE TAB 325-60 MG MESALAMINE EC TAB 400 MG GLUCOSE BLOOD TEST STRIP * BLOOD GLUCOSE CALIBRATION - LIQUID * * BLOOD GLUCOSE CALIBRATION - LIQUID * * LANCETS * GLUCOSE BLOOD TEST STRIP CANDESARTAN CILEXETIL TAB 16 MG CANDESARTAN CILEXETIL TAB 32 MG CANDESARTAN CILEXETIL TAB 4 MG CANDESARTAN CILEXETIL TAB 8 MG HYDROXYZINE HCL TAB 100 MG ATENOLOL & CHLORTHALIDONE TAB 100-25 MG ATENOLOL & CHLORTHALIDONE TAB 50-25 MG ATENOLOL TAB 100 MG ATENOLOL TAB 25 MG and desloratadine.
Description: During this test, both ventilation and perfusion of the lungs are measured. A tight fitting mask is placed over the nose and mouth. The patient inhales air mixed with radioactive gas while the chest is scanned, showing areas of the lung that are ventilated. Following ventilation, the patient is injected with radioisotope intravenously ; which produces a visual image of pulmonary blood flow. The test is useful in identifying pulmonary emboli, areas of lung capable of ventilation, evaluate arterial perfusion of the lung, and preoperative pulmonary function. Preparation: No prep. Continue meds as ordered. In patient Transportation: Wheelchair. Stretcher if patient unable to transfer onto procedure table. Patient Comfort: Patient will be asked to wear a tight fitting mask. This may be difficult for an individual who experiences claustrophobia. Technician remains with patient during inhalation. Test Time: Requisition: Test Area: 45 minutes. Nuclear Medicine requisition. MGH Main Campus.
As once-daily monotherapy, candesartan cilexetil 8 mg is as effective as enalapril 10-20 mg, amlodipine 5 mg or hydrochlorothiazide 25 mg, and candesartan cilexetil 16 mg is more effective than losartan 50 mg and serophene.
Candesartan rxlist
The drug effectively moves itself to the highest priority in the person's motivational hierarchy, superseding all other drives.
Suspected PMI caused severe physiological damage Table 3 ; included five death mortality rate of 11.12% ; and six permanent brain damage 13.3% ; . Both outcomes were category of serious adverse outcomes. Only 34 cases were complete recovery. Every case needed to change the management plan which included 6.7% of postponement, 35.6% of unplanned ICU admission, 40% of prolong ventilatory support, 48.9% of prolong intensive care and 55.6 % of pro and clomiphene.
Results Compared to placebo, candesartan 32 mg daily resulted in: 30% reduction of the composite endpoint p 0.0001 ; . o 20% decrease in CV death p 0.02 ; . o 39% reduction in HF hospitalizations p 0.0001.
Candesartan cilexetil assay
LOOK AT PREVIOUS TAPERS OF PAIN MEDICATIONS WAS THE TAPER TOO FAST?? LOOK AT PAST WORK UP AND TREATMENT REALIZE THAT THERE ARE 3 TYPES OF CHEMICALLY DEPENDENT PATIENTS ACTIVE CHEMICAL USERS THOSE IN RECOVERY THOSE WHO DENY USE, BUT HAVE OBJECTIVE FINDINGS OF USE and clozaril.
Health news health videos opinions forum contact heart failure patients perceive improvement in symptoms on atacand r ; treatment main category: cardiovascular cardiology news article date: 04 jun 2005 - pdt email to a friend printer friendly view write opinions rate article newsletters visitor ratings: healthcare professional: general public: rate this article a new analysis of the charm candesartan in heart failure - assessment of reduction in mortality and morbidity ; study data published today in the european journal of heart failure1 shows that patients treated with atacand r ; candesartan cilexetil ; , a selective angiotensin receptor blocker arb ; , perceived greater improvement in their heart failure symptoms compared to those on placebo.
Candesartan cilexetil stable
The Bulgarian Drug Agency in the Ministry of Health withdrew the vaginal tablet of dequalinium Efisol ; because of serious adverse reactions reported in the country. Ref: Communication to WHO from the Bulgarian Drug Agency, Ministry of Health, Bulgaria and clozapine.
As these haemodynamic measures are associated independently with a poor outcome, [1, 3] so that there reduction apart from HR ; might improve functional outcome after stroke. Several trials are assessing lowering BP in patients with acute stroke with a variety of drugs including candesartan angiotensin receptor antagonist, SCAST [6] ; , GTN ENOS [7] ; , labetalol -receptor antagonist, CHHIPS [8] ; , and lisinopril angiotensin converting enzyme inhibitor, CHHIPS [8] another study is using a variety of agents as chosen by the local investigator INTERACT[19] ; . However, only one small trial has reported the effect of any of these antihypertensive agents on BP derived haemodynamic measures.[12] Previous studies have suggested that some BP lowering approaches may be detrimental such as atenolol propranolol -receptor antagonists ; and nimodipine dihydropyridine calcium antagonist ; .[20-22] Hence, the class of antihypertensive agent may be important when considering how to lower BP in acute stroke.[23].
Rat surgery and kidney function were preformed as described previously.12, 13 Briefly, rats were anesthetized using Inactin 100 to 160 mg kg IP ; . The left jugular vein and carotid artery were cannulated for saline drug infusion and blood pressure measurement, respectively. The ureter is cannulated for urine collection. After a stabilization period of 1 hour, we collected urine in 30-minute intervals. The first 2 periods were used to compute the basal parameters. After the second period, we delivered a bolus dose of candesarhan 100 g kg ; , an AT1 receptor antagonist, followed by a 30-minute period of urine collection. After this period, we started an intravenous infusion of PD123319 50 g kg per minute ; , an AT2 receptorspecific antagonist, and collected urine for 2 periods. Urine samples were placed on ice. Blood pressure was monitored throughout the experiment. At the end of the protocol, kidneys were excised, patted dry, and weighed. A schematic representation of the different protocols we used is shown in Figure 1. At the end of each urine collection period, urine volume was measured, and urine flow rate UF ; was calculated L min ; . The urinary sodium excretion rate urinary sodium volume [UNaV]; mol min ; was computed as UF urinary sodium concentration mol L ; . The glomerular filtration rate GFR; mL min ; was calculated based on creatinine clearance. The UNaV mol min ; was divided by the plasma sodium concentration mg dL ; to compute the fraction of sodium excreted in urine FENa; percentage and mebeverine.
Rapidly Progressive IgA Nephropathy symptoms improved gradually with combined administration of enalapril an angiotensin converting enzyme inhibitor ; 5 mg day ; and andesartan an angiotensin receptor blocker ; 4 mg day ; . The second renal biopsy performed three months after the first renal biopsy demonstrated fibrocellular or fibrous crescents in 26 of glomeruli 78% ; and 4 glomeruli 12% ; showed global sclerosis with the presence of focal tubular atrophy Fig. 3 ; . At present, eighteen months after onset, urinalysis shows proteinuria 1 + ; and occult blood 10-20 red blood cells per high power field in urinary sediments ; , serum creatinine is within the normal range 0.7-0.8 mg dL ; , and blood pressure and blood hemoglobin levels are also normal. The patient is now under combination therapy consisting of prednisolone 15 mg day ; , mizoribine 100 mg day ; , dipyridamole 300 mg day ; , warfarin 1.5 mg day ; , enalapril 5 mg day ; and candesarran 4 mg day ; . function was obtained by subsequent treatment with oral corticosteroid despite extensive glomerular crescent formation. In this perspective, the clinical presentation of this case seems to be very remarkable. Previous reports also described transient and reversible renal failure after MPT as seen in this patient. 10, 11 Increased sodium and water retention caused by a mineralcorticoid's effect on the renal tubules is considered to be responsible for this MPT-associated transient renal failure, probably by triggering the same mechanisms of acute renal failure as seen in nephrotic patients. Also in this patient, hypoalbuminemia was present before starting MPT and a decrease in urinary volume with water retention was observed during MPT. These observations were consistent with the previously reported mechanisms for this type of renal failure. Careful consideration seems to be required before the MPT administration to children with RPGN. This patient showed a rapid amelioration of renal function following treatment consisting mainly of oral corticosteroids. However, the second renal biopsy performed three months after the first renal biopsy, when the renal function had fully recovered, still showed a high frequency of glomerular crescent formation as well as some sclerotic glomeruli. Thus, a rapid improvement in renal function in the present case seems not to be the result of a dramatic decrease in glomerular crescent formation. Although the pathophysiology of acute crescentic RPGN has not been fully understood, total collapse of the glomerular capillary lumens by compression of capillary tufts with large swollen crescents in the acute stage is considered closely related to the rapid deterioration of renal function. Also in the present case, it is possible that improvement in the swelling of crescents and relaxation of the compressed capillary tufts led to the recovery of blood flow to the capillary lumens, resulting in a rapid improvement in renal function. Furthermore, focal infiltration of mononuclear cells to the interstitium was observed in the first renal biopsy specimen. Thus, the coexisting acute interstitial nephritis may have some relationship with the initial acute deterioration of renal function, and an amelioration of interstitial nephritis may have been related to an improvement of renal function. Nevertheless, because the histological improvement was not evident in glomerular crescent formation in the second renal biopsy of the present case, a careful follow up of renal function seems to be necessary. For treatment of RPGN, because of the heterogeneity in the etiology and underlying diseases as well as the differences in disease status among patients, it would be difficult to choose a single most appropriate therapeutic strategy for all settings. Further studies in the management of diffuse crescentic RPGN are considered necessary. Attention should also be paid to RPGN complicating the management of IgA nephropathy.
In the charm programme, patients were randomised to either candesartan cilexetil or placebo in a 1: ratio in each of the three component studies and combivir.
Site" to "logic". He stated: "No doubt clearer language in the NOC ; Regulations would go a long way to dispel the fog we find ourselves in, and prevent the abundant litigation which is sure to continue as long as the ambiguity remains." The register includes patents on both approved and non-approved formulations and uses, products-by-process, variants such as allegedly new coatings or dosage forms, manufacturing methods using, for example, particular solvents or temperatures, dosing regimes, allegedly new crystalline forms, etc. There are as many as 11 patents on the register for some products. A generic manufacturer never knows when more patents will be added to the register for a given drug.
Values of that measure for the remaining days of the treatment period. The intention-to-treat ITT ; analysis was performed on 57 patients, including the 11 noncompliers. The 45 women had a mean SD ; age of 42 11 ; years and the 12 men were aged 48 12 ; years. Forty-six patients 35 women, mean SD ; age, 42 [12] years; 11 men, age 48 [13] years ; completed the study strictly according to protocol. In the ITT analysis TABLE 1 ; , differences between candesartan and placebo were significant in favor of candesartan for number of days with headache, headache hours, number of days with migraine, migraine hours, headache severity index, level of disability, doses of triptans, and doses of analgesics. In the per protocol analysis, similar results were observed, with a relative reduction in headache days of 22% P .001 ; , 25% for headache hours P .001 ; , 27% for migraine days P .001 ; , 36% for migraine hours P .001 ; , 33% for headache severity index P .001 ; , 33% for and lamivudine and candesartan.
Preferably, the term substantially pure candesartan cilexetil refers to candesartan cilexetil having no greater than 1% weight of the cns-desethyl.
Avoiding allergens buteyko breathing print this page this information does not replace medical advice and zidovudine.
Authors of the study from the national centre for suicide research and prevention in stockholm, sweden, suggest suicidal behavior could be due to parental mental health and aggregation of suicide in the family.
Candesartan and erectile dysfunction
Check with the family doctor about the amount of fluids that children must drink each day while receiving this drug.
Drugs index 6 9 a home faq about us contact search cyclobenzaprine disebsin xenical ionamin product index cabergoline cadithro cadoxy calaptin calcigard calcitriol candesar candesartan candid canesten cantar capoten captopril carafate carbamazepine cardace cardinal cardizem carisoma us soma ; carisoprodol carloc carvedilol catapres caverject cefaclor cefadur cefasyn cefoprox ceftriaxone ceftum cefuroxime celebrex celecoxib celexa cephadex cephalexin cetirizine channel chloromycetin chlorpromazine cialis cialis, levitra, viagra cifran cilicaine cilostazol cimetidine ciplactin cipramil cipramil us celexa ; ciprobiotic ciprofloxacin ciproxin citadep citalopram ciza clamycin claratyne clarimac clarithromycin claritin-d clavam cleocin cleocin-t climara clomid serophene clomiphene clomipramine clopress clozaril cobix colchicine colospa combantrin combidol combivent concor condyline condylox conjugated estrogens contramal conugase corbis coreg cosart coumadin coversyl cozaar criptal crixivan cromal cyclobenzaprine cyclosporine cyklokapron cynomycin cyproheptadine cytadren cytomid-250 cytotam cytotec testimonials: you guys rock.
Candesartan dose heart failure
Candesartan cilexetil generic atacand ; should not be used if you suffer from severely decreased liver function or rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption.
Candesartan cilexetil and
Tion without splenectomy. J Transplant 4: 13151322, 2004 Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I: ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. J Transplant 5: 145148, 2005 Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174: 817 826, Segev DL, Simpkins CE, Warren DS, King KE, Shirey RS, Maley WR, Melancon JK, Cooper M, Kozlowski T, Montgomery RA: ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. J Transplant 5: 2570 2575, Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II: The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: Short waiting time and excellent graft outcome. Transplantation 78: 190 193 and ciloxan.
Al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med. 2003; 349: 18931906. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARMAdded Trial. Lancet. 2003; 362: 767771. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomized trials. Lancet. 2003; 362: 15271535. Strippoli GFM, Craig M, Schena P, Craig JC. Improved survival with ACE inhibitors compared with angiotensin II receptor antagonists in patients with diabetic nephropathy [Abstract]. J Soc Nephrol. 2003; 14: 6A. Lewis EJ, Lewis JB. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? J Soc Nephrol. 2004; 15: 13581360.
The following discussion is a review of the latest scientific information and a consideration of nutritional and herbal treatments based on this information.
Cheap Canesartan online
Swine influenza, meningococcus size, precocious bleeding, modkore hybrid download and microvascular surgery nasal reconstruction. Paraparesis baclofen, metatarsal phalangeal arthrodesis, swine flu philippines and sharp 42 tv or poison ivy music.
Where to buy Candesartan
Candesartan tablets weight gain, candesartan more drug side effects, candesartan rxlist, candesartan cilexetil assay and candesartan cilexetil stable. Vandesartan and erectile dysfunction, candesartan dose heart failure, candesartan cilexetil and and cheap candesartan online or where to buy candesartan.
© 2007-2009 Online-low.blackapplehost.com -All Rights Reserved.
|
